NASDAQ · ENGNW
Healthcare · Biotechnology
$0.23
Up+$0.00 (+0.00%)
Updated Sep 13, 2026, 7:14 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 13 trading sessions · Daily adjusted prices
ENGNW closed at $0.23 after 13 trading sessions, down 6.01% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.23 | $0.23 | $0.23 | $0.23 | 1.81K |
| Sep 4, 2026 | $0.22 | $0.23 | $0.22 | $0.23 | 1.21K |
| Sep 3, 2026 | $0.2398 | $0.2399 | $0.22 | $0.22 | 6.75K |
| Sep 2, 2026 | $0.22 | $0.23 | $0.1999 | $0.22 | 15.33K |
| Sep 1, 2026 | $0.2101 | $0.249 | $0.185 | $0.1953 | 28.49K |
| Aug 31, 2026 | $0.2681 | $0.2681 | $0.2681 | $0.2681 | 550 |
| Aug 28, 2026 | $0.23 | $0.2681 | $0.23 | $0.23 | 36.01K |
| Aug 27, 2026 | $0.2491 | $0.2491 | $0.23 | $0.23 | 842 |
| Aug 25, 2026 | $0.222 | $0.2488 | $0.1801 | $0.1801 | 56.82K |
| Aug 24, 2026 | $0.2952 | $0.2952 | $0.2952 | $0.2952 | 500 |
| Aug 21, 2026 | $0.4301 | $0.4301 | $0.2508 | $0.4301 | 2.4K |
| Aug 20, 2026 | $0.2502 | $0.2502 | $0.2502 | $0.2502 | 100 |
| Aug 17, 2026 | $0.2126 | $0.2575 | $0.19 | $0.2447 | 48.1K |
The latest Smart Investors Daily articles mentioning ENGNW.
ENGNW research
Company profile and research snapshot.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Sep 8, 2026
BOSTON & MONTREAL, September 08, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates.
Yahoo · Sep 1, 2026
BOSTON & MONTREAL, September 01, 2026--enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:
Yahoo · Aug 13, 2026
enGene (NASDAQ:ENGN) outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystecto
SeekingAlpha · Aug 11, 2026
enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer August 11, 2026 11:00 AM EDTCompany...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ENGNW.
